ValiRx (AIM:VAL), the AIM-listed life science company focused on early-stage cancer therapeutics and women's health, said its majority-owned subsidiary Cytolytix has received notification of intention to grant a second European patent.
The new patent builds on the European grant of Cytolytix's original peptide formulation patent, "Nanoparticle for Anti-Cancer Peptides and Uses Thereof", announced on 27 May.
ValiRx said the two patent families strengthen Cytolytix's intellectual property position and support ongoing licensing and partnership discussions. Separately, ValiRx filed for additional patent protection on 26 May covering a second-generation delivery platform based on novel lipid formulations of its oncolytic peptide.
The new filing includes data showing the platform induces immunogenic cell death, a form of cell death that alerts the immune system, in triple negative breast cancer cells.
Mark Eccleston, chief executive of ValiRx, said the notice "is a significant milestone for Cytolytix, confirming the novelty of the platform and providing a solid base to build on with further IP developed in house."
He added that the immune-activating data supports the company's comparative oncology approach, which tests therapies in pet patients with naturally occurring tumours alongside human patients with intact immune systems.
Eccleston credited expertise from Inaphaea and partners ScreenIn3D, Voxcell and Bioreparia for advancing the platform's development.
ValiRx said a further announcement will follow once the second patent is formally granted.
News Intelligence what this means for the company
Cytolytix, ValiRx's majority-owned subsidiary, has received a notice of intention to grant a second European patent for its cancer peptide platform, following an earlier grant in May. The patent notification strengthens the IP portfolio ahead of formal grant and supports ongoing licensing and partnership discussions, but remains a pre-grant milestone rather than a commercial or clinical advance.
The second patent notice extends Cytolytix's IP moat and may improve terms in licensing negotiations, but does not alter the company's stage (preclinical/early-stage) or timeline to clinical validation. Patent grants alone do not reduce development risk or generate revenue.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
